Search

Your search keyword '"Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 ' showing total 16 results
Start Over Author "Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816
16 results on '"Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 '

1. The first effect of COVID-19 pandemic on starting biological disease modifying anti-rheumatic drugs: outcomes from the TReasure real-life database

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kiraz, Sedat; Dalkilic, Ediz; Kimyon, Gezmis; Mercan, Ridvan; Karadag, Omer; Bes, Cemal; Kilic, Levent; Akar, Servet; Ates, Askin; Emmungil, Hakan; Ertenli, Ihsan; Pehlivan, Yavuz; Coskun, Belkis Nihan; Yagiz, Burcu; Ersozlu, Duygu; Gonullu, Emel; Cinar, Muhammet; Kasifoglu, Timucin; Koca, Suleyman Serdar; Karasu, Ugur; Kucuksahin, Orhan; Kalyoncu, Umut, School of Medicine, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kiraz, Sedat; Dalkilic, Ediz; Kimyon, Gezmis; Mercan, Ridvan; Karadag, Omer; Bes, Cemal; Kilic, Levent; Akar, Servet; Ates, Askin; Emmungil, Hakan; Ertenli, Ihsan; Pehlivan, Yavuz; Coskun, Belkis Nihan; Yagiz, Burcu; Ersozlu, Duygu; Gonullu, Emel; Cinar, Muhammet; Kasifoglu, Timucin; Koca, Suleyman Serdar; Karasu, Ugur; Kucuksahin, Orhan; Kalyoncu, Umut, and School of Medicine

Abstract

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic., NA

Published
2023

2. Analysis of the prophylactic use of hydroxychloroquine at the beginning of the COVID-19 pandemic among physicians

Author

Gönenli, Mehmet Gökhan (ORCID 0000-0003-2925-7048 & YÖK ID 350445); Kayı, İlker (ORCID 0000-0002-4115-6613 & YÖK ID 168599); Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432); Nalbantoğlu, Emine Ayça (ORCID 0000-0002-7405-0591 & YÖK ID 327621); Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Baydas, Tuba; Kose, Murat; Keskinler, Mirac Vural; Akpinar, Timur Selcuk, Koç Üniversitesi İş Bankası Enfeksiyon Hastalıkları Uygulama ve Araştırma Merkezi (EHAM) / Koç University İşbank Center for Infectious Diseases (KU-IS CID), School of Medicine, Gönenli, Mehmet Gökhan (ORCID 0000-0003-2925-7048 & YÖK ID 350445); Kayı, İlker (ORCID 0000-0002-4115-6613 & YÖK ID 168599); Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432); Nalbantoğlu, Emine Ayça (ORCID 0000-0002-7405-0591 & YÖK ID 327621); Ergönül, Mehmet Önder (ORCID 0000-0003-1935-9235 & YÖK ID 110398), Baydas, Tuba; Kose, Murat; Keskinler, Mirac Vural; Akpinar, Timur Selcuk, Koç Üniversitesi İş Bankası Enfeksiyon Hastalıkları Uygulama ve Araştırma Merkezi (EHAM) / Koç University İşbank Center for Infectious Diseases (KU-IS CID), and School of Medicine

Abstract

Objective: throughout the pandemic, physicians working at the frontlines have embarked on various quests to protect themselves, and many physicians preferred using hydroxychloroquine (HQN) as a prophylactic agent. This study aimed to investigate the reasons leading physicians to use HQN and its effects on them. Materials and Methods: this study is cross-sectional with a target population of physicians working in pandemic hospitals in Istanbul, Turkey. We invited participants from seven hospitals via email between May 14 and June 13, 2020. An online questionnaire, including 57 questions, was sent to physicians. Results: a total of 148 (26%) physicians out of 564 participants had used hydroxychloroquine for prevention. Older physicians and those with a history of exposure to COVID-19 patients without protection used prophylactic HQN more frequently. The use of HQN did not differ statistically in terms of being infected among the exposed physicians (p=0.52). Nineteen (13%) physicians using HQN developed side effects related to the drug. Diarrhea and nausea were the most common. Conclusion: prophylactic HQN use was more common among physicians older than 40 years and with higher exposure rates to a COVID-19 patient without protection. The physicians working on the front line had the highest rate of infection. HQN was not effective in the prophylaxis of COVID-19 among the exposed physicians., NA

Published
2022

3. An unusual case of extrapulmonary tuberculosis in rheumatology consultation

Author

Somay, Kayra; Eren, İlker (ORCID 0000-0003-2965-7690 & YÖK ID 168021); Kapmaz, Mahir; Çağlayan, Benan Niku (ORCID 0000-0002-6131-157X & YÖK ID 230719); Karakaya, Afak Durur (ORCID 0000-0003-3604-6791 & YÖK ID 269567); Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Koç University Hospital, School of Medicine, Somay, Kayra; Eren, İlker (ORCID 0000-0003-2965-7690 & YÖK ID 168021); Kapmaz, Mahir; Çağlayan, Benan Niku (ORCID 0000-0002-6131-157X & YÖK ID 230719); Karakaya, Afak Durur (ORCID 0000-0003-3604-6791 & YÖK ID 269567); Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Koç University Hospital, and School of Medicine

Abstract

N/A, NA

Published
2022

4. COVID-19 among patients with inflammatory rheumatic diseases

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Esatoğlu, Sinem Nihal; Taşçılar, Koray; Babaoğlu, Hakan; Bes, Cemal; Yurttaş, Berna; Akar, Servet; Pehlivan, Özlem; Akleylek, Cansu; Tecer, Duygu; Seyahi, Emire; Yüce-İnel, Tuba; Bodakçi, Erdal; Tekgöz, Emre; Çolak, Seda; Bölek, Ertuğrul Çağrı; Koca, Süleyman Serdar; Kalyoncu, Umut; İçaçan, Ozan Cemal; Uğurlu, Serdal; Öz, Hande Ece; Hamuryudan, Vedat; Hatemi, Gülen; Turkish Society Rheumatology COVID-19, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), and Esatoğlu, Sinem Nihal; Taşçılar, Koray; Babaoğlu, Hakan; Bes, Cemal; Yurttaş, Berna; Akar, Servet; Pehlivan, Özlem; Akleylek, Cansu; Tecer, Duygu; Seyahi, Emire; Yüce-İnel, Tuba; Bodakçi, Erdal; Tekgöz, Emre; Çolak, Seda; Bölek, Ertuğrul Çağrı; Koca, Süleyman Serdar; Kalyoncu, Umut; İçaçan, Ozan Cemal; Uğurlu, Serdal; Öz, Hande Ece; Hamuryudan, Vedat; Hatemi, Gülen; Turkish Society Rheumatology COVID-19

Abstract

Background: the course of novel coronavirus disease 2019 (COVID-19) has been of special concern in patients with inflammatory rheumatic diseases (IRDs) due to the immune dysregulation that may be associated with these diseases and the medications used for IRDs, that may affect innate immune responses. Objective: in this cohort study, we aimed to report the disease characteristics and variables associated with COVID-19 outcome among Turkish patients with IRDs. Methods: between April and June, 2020, 167 adult IRD patients with COVID-19 were registered from 31 centers in 14 cities in Turkey. Disease outcome was classified in 4 categories; (i) outpatient management, (ii) hospitalization without oxygen requirement, (iii) hospitalization with oxygen requirement, and (iv) intensive care unit (ICU) admission or death. Multivariable ordinal logistic regression analysis was conducted to determine variables associated with a worse outcome. Results: 165 patients (mean age: 50 ± 15.6 years, 58.2% female) were included. Twenty-four patients (14.5%) recovered under outpatient management, 141 (85.5%) were hospitalized, 49 (30%) required inpatient oxygen support, 22 (13%) were treated in the ICU (17 received invasive mechanic ventilation) and 16 (10%) died. Glucocorticoid use (OR: 4.53, 95%CI 1.65-12.76), chronic kidney disease (OR: 12.8, 95%CI 2.25-103.5), pulmonary disease (OR: 2.66, 95%CI 1.08-6.61) and obesity (OR: 3.7, 95%CI 1.01-13.87) were associated with a worse outcome. Biologic disease-modifying antirheumatic drugs (DMARDs) do not seem to affect COVID-19 outcome while conventional synthetic DMARDs may have a protective effect (OR: 0.36, 95%CI 0.17-0.75). Estimates for the associations between IRD diagnoses and outcome were inconclusive. Conclusions: among IRD patients with COVID-19, comorbidities and glucocorticoid use were associated with a worse outcome, while biologic DMARDs do not seem to be associated with a worse outcome.

Published
2021

5. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), and Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat

Abstract

Background/aim: to evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: a total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: a total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.

Published
2021

6. Granulomatosis with Poliangiitis (GPA)

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432); Şentürk, Begüm Güler (ORCID 0000-0002-4806-317X & YÖK ID 327593), School of Medicine, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432); Şentürk, Begüm Güler (ORCID 0000-0002-4806-317X & YÖK ID 327593), and School of Medicine

Abstract

NA, NA

Published
2021

7. Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Pehlivan, Özlem; Omma, Ahmet; Can-Sandıkçı, Sevinç; Girgin, Sinem; İçaçan, Ozan Cemal; Çelik, Selda; Bes Cemal, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), and Pehlivan, Özlem; Omma, Ahmet; Can-Sandıkçı, Sevinç; Girgin, Sinem; İçaçan, Ozan Cemal; Çelik, Selda; Bes Cemal

Abstract

Physicians are challenged by the recognition and treatment of older patients with rheumatoid arthritis (RA). The aim of this case-control study was to evaluate the retention and safety of conventional disease-modifying anti-rheumatic drugs in older patients with RA.In this observational case-control study, we assessed older patients with RA (≥65 years) who were diagnosed in 3 different rheumatology centers from Turkey. Patients were divided as to those aged ≥65 years (elderly rheumatoid arthritis [ERA]) and those aged <65 years (young rheumatoid arthritis [YRA]) at the time of conventional DMARD treatment initiation. The Mann-Whitney U test was used for the comparison of 2 non-normally distributed groups. The Chi-square (χ) test was used for categorical variables. Survival analysis were performed using the Kaplan-Meier method.Four hundred eighteen patients with RA (296 females [71%]) were included from January 2010 to January 2018. The age of treatment onset of 190 (47%) patients was in the elderly period and they were included in the ERA group. In the analysis of drug retention rates, there was no significant difference between the ERA and YRA groups for each conventional DMARD (methotrexate 71.2% in ERA, 62.7% in YRA, P = .817; hydroxychloroquine 82.9% in ERA, 78.8% in YRA, P = .899; leflunomide 81.4% in ERA, 84.4% in YRA, P = .205; sulfasalazine 37.5% in ERA, 40.9% in YRA, P = .380). The adverse event data were also similar in both groups.The drug retention and adverse effect rates in older patients with RA using conventional DMARDS are similar to the rates in young patients with RA.

Published
2020

8. The effect of metabolic syndrome on cardiovascular disease and cumulative organ damage in Takayasu's arteritis

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Tahra, Sema Kaymaz; Yazıcı, Ayten; Çefle, Ayşe; Kara, Mete; Yarkan-Tuğsal, Handan; Gerçik, Önay; Akar, Servet; Önen, Fatoş; Aksu, Kenan; Keser, Gökhan; Bes, Cemal; Kamalı, Sevil; Alibaz-Öner, Fatma; Direskeneli, Haner, School of Medicine, Department of Internal Diseases, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Tahra, Sema Kaymaz; Yazıcı, Ayten; Çefle, Ayşe; Kara, Mete; Yarkan-Tuğsal, Handan; Gerçik, Önay; Akar, Servet; Önen, Fatoş; Aksu, Kenan; Keser, Gökhan; Bes, Cemal; Kamalı, Sevil; Alibaz-Öner, Fatma; Direskeneli, Haner, School of Medicine, and Department of Internal Diseases

Abstract

MSD; Abbvie; Roche; UCB; Novartis; Pfizer; Amgen

Published
2019

9. Smoking may be related to sacroiliitis in enteropathic arthritis patients: treasure real-life preliminary data

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Küçükşahin, Orhan; Erden, Abdulsamet; İlgen, Ufuk; Kiraz, Sedat; Ertenli, Ali İhsan; Bilge, Nazife Şule Yaşar; Kaşifoğlu, Timuçin; Dalkılıç, Ediz; Bes, Cemal; Emmungil, Hakan; Atagündüz, Pamir; Şeniz, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Aşkın; Akar, Servet; Gercik, Onay; Ersözlü, Duygu; Yazısız, Veli; Kimyon, Gezmiş; Aydın, Müge; Mercan, Rıdvan; Oz, Burak; Akar, Zeynel Abidin; Karadağ, Omer; Keleşoğlu, Bahar; Yılmaz, Sedat; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıc, Levent; Erten, Şükran; Taşçılar, Koray; Kalyoncu, Umut, School of Medicine, Department of Internal Diseases, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Küçükşahin, Orhan; Erden, Abdulsamet; İlgen, Ufuk; Kiraz, Sedat; Ertenli, Ali İhsan; Bilge, Nazife Şule Yaşar; Kaşifoğlu, Timuçin; Dalkılıç, Ediz; Bes, Cemal; Emmungil, Hakan; Atagündüz, Pamir; Şeniz, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Aşkın; Akar, Servet; Gercik, Onay; Ersözlü, Duygu; Yazısız, Veli; Kimyon, Gezmiş; Aydın, Müge; Mercan, Rıdvan; Oz, Burak; Akar, Zeynel Abidin; Karadağ, Omer; Keleşoğlu, Bahar; Yılmaz, Sedat; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıc, Levent; Erten, Şükran; Taşçılar, Koray; Kalyoncu, Umut, School of Medicine, and Department of Internal Diseases

Abstract

MSD; Abbvie; Roche; Pfizer; UCB; Novartis; Amgen

Published
2019

10. The prevalence of non-vascular pulmonary manifestations in patients with Takayasu' arteritis: a retrospective multi-centered cohort study

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Yazıcı, Ayten; Çefle, Ayşe; Tahra, Sema Kaymaz; Kara, Mete; Gerçik, Önay; Tuğsal, Handan Yarkan; Önen, Fatoş; Akar, Servet; Aksu, Kenan; Keser, Gokhan; Alibaz-Öner, Fatma; Direskeneli, Haner, School of Medicine, Department of Internal Diseases, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Yazıcı, Ayten; Çefle, Ayşe; Tahra, Sema Kaymaz; Kara, Mete; Gerçik, Önay; Tuğsal, Handan Yarkan; Önen, Fatoş; Akar, Servet; Aksu, Kenan; Keser, Gokhan; Alibaz-Öner, Fatma; Direskeneli, Haner, School of Medicine, and Department of Internal Diseases

Abstract

MSD; Abbvie; Roche; UCB; Novartis; Pfizer; Amgen

Published
2019

11. Derivation and validation of a new Still activity score (SAS)

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kalyoncu, Umut; Kaşifoğlu, Timuçin; Omma, Ahmet; Bes, Cemal; Çınar, Muhammet; Emmungil, Hakan; Küçükşahin, Orhan; Akar, Servet; Aksu, Kenan; Yıldız, Fatih; Erden, Abdulsamet; Bilgin, Emre; Turan, Sezin; Dalkılıç, Ediz; Ermurat, Selime; Hayran, Kadir Mutlu, School of Medicine, Department of Internal Diseases, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kalyoncu, Umut; Kaşifoğlu, Timuçin; Omma, Ahmet; Bes, Cemal; Çınar, Muhammet; Emmungil, Hakan; Küçükşahin, Orhan; Akar, Servet; Aksu, Kenan; Yıldız, Fatih; Erden, Abdulsamet; Bilgin, Emre; Turan, Sezin; Dalkılıç, Ediz; Ermurat, Selime; Hayran, Kadir Mutlu, School of Medicine, and Department of Internal Diseases

Abstract

Roche; UCB; Novartis; Pfizer; MSD; Abbvie; Amgen

Published
2019

12. Uveitis related factors in patients with spondyloarthritis

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Bilge, Nazife Şule Yaşar; Kaşifoğlu, Timuçin; Kiraz, Sedat; Ertenli, Ali İhsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Bes, Cemal; Emmungil, Hakan; Atagündüz, Pamir; Şeniz, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Aşkın; Akar, Servet; Ersözlü, Duygu; Yazısız, Veli; Kimyon, Gezmiş; Tufan, Müge Aydın; Mercan, Rıdvan; Erden, Abdulsamet; Bodakçı, Erdal; Gerçik, Önay; Oz, Burak; Akar, Zeynel Abidin; Karadağ, Ömer; Dinçer, Bahar; Yılmaz, Sedat; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Gönüllü, Emel; Erten, Şükran; Turan, Sezin; Taşçılar, Koray; Kalyoncu, Umut, School of Medicine, Department of Internal Diseases, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Bilge, Nazife Şule Yaşar; Kaşifoğlu, Timuçin; Kiraz, Sedat; Ertenli, Ali İhsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Bes, Cemal; Emmungil, Hakan; Atagündüz, Pamir; Şeniz, Belkıs Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Aşkın; Akar, Servet; Ersözlü, Duygu; Yazısız, Veli; Kimyon, Gezmiş; Tufan, Müge Aydın; Mercan, Rıdvan; Erden, Abdulsamet; Bodakçı, Erdal; Gerçik, Önay; Oz, Burak; Akar, Zeynel Abidin; Karadağ, Ömer; Dinçer, Bahar; Yılmaz, Sedat; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Gönüllü, Emel; Erten, Şükran; Turan, Sezin; Taşçılar, Koray; Kalyoncu, Umut, School of Medicine, and Department of Internal Diseases

Abstract

MSD; Abbvie; Roche; Pfizer; UCB; Novartis

Published
2019

13. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Author

Orhan Küçükşahin, Servet Akar, Emel Gönüllü, Duygu Ersözlü, Sedat Kiraz, Gezmiş Kimyon, Hakan Emmungil, Umut Kalyoncu, Ali İhsan Ertenli, Nihan Coşkun, Emre Bilgin, Rıdvan Mercan, Yavuz Pehlivan, Omer Karadag, Hüseyin Dalkiliç, Cemal Bes, Süleyman Serdar Koca, Burcu Yağız, Nilüfer Alpay Kanıtez, Timuçin Kaşifoğlu, Seda Colak, Elif Durak Ediboglu, Levent Kilic, İç Hastalıkları, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kalyoncu, Umut, Pehlivan, Yavuz, Akar, Servet, Kaşifoğlu, Timuçin, Kimyon, Gezmiş, Karadağ, Ömer, Dalkılıç, Ediz, Ertenli, Ali İhsan, Kılıç, Levent, Ersözlü, Duygu, Beş, Cemal, Emmungil, Hakan, Mercan, Rıdvan, Ediboğlu, Elif Durak, Bilgin, Emre, Çolak, Seda, Koca, Süleyman Serdar, Gönüllü, Emel, Küçükşahin, Orhan, Coşkun, Nihan, Yağız, Burcu, Kiraz, Sedat, Koç University Hospital, and School of Medicine

Subjects
rheumatoid arthritis, Male, Bath ankylosing spondylitis disease activity index, Inflammatory arthritis, polymerase chain reaction, very elderly, health status, Disease, Arthritis, Rheumatoid, Cohort Studies, rituximab, adalimumab, Pandemic, middle aged, disease modifying antirheumatic drug, Health Assessment Questionnaire, Prospective Studies, Registries, golimumab, Aged, 80 and over, register, Ankylosing Spondylitis Disease Activity Score, secukinumab, adult, medication compliance, Simplified Disease Activity Index, Biologic DMARDs, General Medicine, spondyloarthritis, Middle Aged, cohort analysis, aged, female, spondylarthritis, Rheumatoid arthritis, drug withdrawal, Antirheumatic Agents, young adult, Rituximab, Female, biologic DMARDs, medicine.drug, prospective study, Adult, medicine.medical_specialty, abatacept, hydroxychloroquine, Coronavirus disease 2019 (COVID-19), Adolescent, Visual analogue scale, COVID-19, Spondyloarthritis, salazosulfapyridine, methotrexate, Article, Medication Adherence, tocilizumab, coronavirus disease 2019, Young Adult, remission, Internal medicine, medicine, DAS28, Humans, human, Pandemics, Aged, leflunomide, business.industry, SARS-CoV-2, pandemic, questionnaire, General and internal medicine, visual analog scale, medicine.disease, major clinical study, Discontinuation, certolizumab pegol, Bath ankylosing spondylitis functional index, antirheumatic agent, observational study, erythrocyte sedimentation rate, business, infliximab, Crohn Disease Activity Index, etanercept, disease activity
Abstract

Background/aim: to evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: a total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: a total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored., Hacettepe Rheumatology Society

Published
2021

14. COVID-19 Among Patients With Inflammatory Rheumatic Diseases

Author

Sinem Nihal Esatoglu, Koray Tascilar, Hakan Babaoğlu, Cemal Bes, Berna Yurttas, Servet Akar, Ozlem Pehlivan, Cansu Akleylek, Duygu Tecer, Emire Seyahi, Tuba Yuce-Inel, Nilufer Alpay-Kanitez, Erdal Bodakci, Emre Tekgoz, Seda Colak, Ertugrul Cagri Bolek, Suleyman Serdar Koca, Umut Kalyoncu, Ozan Cemal Icacan, Serdal Ugurlu, Hande Ece Oz, Vedat Hamuryudan, Gulen Hatemi, the Turkish Society for Rheumatology COVID-19 Registry Investigators, Ayse Cefle, Ali Karakas, Derya Kaskari, Samet Karahan, Dilek Tezcan, Abdurrahman Tufan, Ayse Ayan, Levent Kılıc, Salim Donmez, Mustafa Erdogan, Veli Yazisiz, Edip Gokalp Gok, Ahmet Eftal Yucel, Elif Dincses Nas, Gezmiş Kimyon, Gunay Sahin Dalgic, Hakan Erdem, Kerem Yigit Abacar, Ridvan Mercan, Omer Karadag, Onay Gercik, Suleyman Ozbek, Sebnem Gider, Semih Gulle, Sibel Osken, Sedat Kiraz, Timucin Kasifoglu, Fatma Alibaz-Oner, Izzet Fresko, Ali Akdogan, Neslihan Yilmaz, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Esatoğlu, Sinem Nihal, Taşçılar, Koray, Babaoğlu, Hakan, Bes, Cemal, Yurttaş, Berna, Akar, Servet, Pehlivan, Özlem, Akleylek, Cansu, Tecer, Duygu, Seyahi, Emire, Yüce-İnel, Tuba, Bodakçi, Erdal, Tekgöz, Emre, Çolak, Seda, Bölek, Ertuğrul Çağrı, Koca, Süleyman Serdar, Kalyoncu, Umut, İçaçan, Ozan Cemal, Uğurlu, Serdal, Öz, Hande Ece, Hamuryudan, Vedat, Hatemi, Gülen, Turkish Society Rheumatology COVID-19, and School of Medicine

Subjects
0301 basic medicine, Male, Multivariate analysis, Turkey, Comorbidity, medicine.disease_cause, DMARDs, law.invention, Cohort Studies, 0302 clinical medicine, law, Ambulatory Care, Immunology and Allergy, Original Research, Middle Aged, Intensive care unit, Hospitalization, Antirheumatic Agents, Regression Analysis, Female, rheumathoid diseases, biologic DMARDs, Cohort study, Adult, medicine.medical_specialty, Critical Care, Immunology, SARS CoV-2, 03 medical and health sciences, Ambulatory care, Internal medicine, Rheumatic Diseases, medicine, Humans, Glucocorticoids, Aged, business.industry, Oxygen Inhalation Therapy, COVID-19, Rheumathoid diseases, Biologic DMARDs, RC581-607, Immune dysregulation, medicine.disease, Obesity, 030104 developmental biology, Multivariate Analysis, Immunologic diseases. Allergy, business, 030215 immunology, Kidney disease
Abstract

Background: the course of novel coronavirus disease 2019 (COVID-19) has been of special concern in patients with inflammatory rheumatic diseases (IRDs) due to the immune dysregulation that may be associated with these diseases and the medications used for IRDs, that may affect innate immune responses. Objective: in this cohort study, we aimed to report the disease characteristics and variables associated with COVID-19 outcome among Turkish patients with IRDs. Methods: between April and June, 2020, 167 adult IRD patients with COVID-19 were registered from 31 centers in 14 cities in Turkey. Disease outcome was classified in 4 categories; (i) outpatient management, (ii) hospitalization without oxygen requirement, (iii) hospitalization with oxygen requirement, and (iv) intensive care unit (ICU) admission or death. Multivariable ordinal logistic regression analysis was conducted to determine variables associated with a worse outcome. Results: 165 patients (mean age: 50 ± 15.6 years, 58.2% female) were included. Twenty-four patients (14.5%) recovered under outpatient management, 141 (85.5%) were hospitalized, 49 (30%) required inpatient oxygen support, 22 (13%) were treated in the ICU (17 received invasive mechanic ventilation) and 16 (10%) died. Glucocorticoid use (OR: 4.53, 95%CI 1.65-12.76), chronic kidney disease (OR: 12.8, 95%CI 2.25-103.5), pulmonary disease (OR: 2.66, 95%CI 1.08-6.61) and obesity (OR: 3.7, 95%CI 1.01-13.87) were associated with a worse outcome. Biologic disease-modifying antirheumatic drugs (DMARDs) do not seem to affect COVID-19 outcome while conventional synthetic DMARDs may have a protective effect (OR: 0.36, 95%CI 0.17-0.75). Estimates for the associations between IRD diagnoses and outcome were inconclusive. Conclusions: among IRD patients with COVID-19, comorbidities and glucocorticoid use were associated with a worse outcome, while biologic DMARDs do not seem to be associated with a worse outcome., NA

Published
2021

15. Granulomatosis with Poliangiitis (GPA)

Author

Begüm Güler Şentürk, Nilüfer Alpay Kanıtez, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Şentürk, Begüm Güler (ORCID 0000-0002-4806-317X & YÖK ID 327593), and School of Medicine

Subjects
Nuclear magnetic resonance, Materials science, Medicine, NA, General Medicine
Abstract

NA

Published
2021

16. Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis

Author

Ozan Cemal Icacan, Ahmet Omma, Özlem Pehlivan, Sinem Girgin, Nilufer Alpay-Kanitez, Sevinç Can-Sandikçi, Selda Çelik, Cemal Bes, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Pehlivan, Özlem, Omma, Ahmet, Can-Sandıkçı, Sevinç, Girgin, Sinem, İçaçan, Ozan Cemal, Çelik, Selda, Bes Cemal, and School of Medicine

Subjects
Male, rheumatoid arthritis, safety, medicine.medical_specialty, Arthritis, Observational Study, elderly, Medication Adherence, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Sulfasalazine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Adverse effect, Leflunomide, Aged, Retrospective Studies, business.industry, Conventional disease, Modifying antirheumatic drugs, Elderly, Retention rates, Rheumatoid arthritis, Safety, Case-control study, Age Factors, Hydroxychloroquine, Medication adherence, Age factors, Antirheumatic agents, General Medicine, Middle Aged, medicine.disease, Rheumatology, retention rates, 030220 oncology & carcinogenesis, Antirheumatic Agents, Case-Control Studies, Female, Patient Safety, business, medicine.drug, Research Article, conventional disease-modifying antirheumatic drugs
Abstract

Physicians are challenged by the recognition and treatment of older patients with rheumatoid arthritis (RA). The aim of this case-control study was to evaluate the retention and safety of conventional disease-modifying anti-rheumatic drugs in older patients with RA.In this observational case-control study, we assessed older patients with RA (≥65 years) who were diagnosed in 3 different rheumatology centers from Turkey. Patients were divided as to those aged ≥65 years (elderly rheumatoid arthritis [ERA]) and those aged, NA

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results